156 related articles for article (PubMed ID: 8610355)
41. Are we near to an effective drug treatment for bronchiolitis obliterans?
Verleden GM; Vos R; Dupont L; Van Raemdonck DE; Vanaudenaerde BM; Verleden SE
Expert Opin Pharmacother; 2014 Oct; 15(15):2117-20. PubMed ID: 25154562
[TBL] [Abstract][Full Text] [Related]
42. Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome.
Karnes HE; Schindler EI; Morrell M; Hachem RR; Berman K; Vedantham S; Atkinson J; Spitznagel E; Despotis GJ
Transplantation; 2019 May; 103(5):1036-1042. PubMed ID: 30130331
[TBL] [Abstract][Full Text] [Related]
43. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.
Kesten S; Chaparro C; Scavuzzo M; Gutierrez C
J Heart Lung Transplant; 1997 Sep; 16(9):905-12. PubMed ID: 9322139
[TBL] [Abstract][Full Text] [Related]
44. The predictive value of bronchiolitis obliterans syndrome stage 0-p.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
Am J Respir Crit Care Med; 2004 Feb; 169(4):468-72. PubMed ID: 14670802
[TBL] [Abstract][Full Text] [Related]
45. Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation.
Reid DW; Walters EH; Johns DP; Ward C; Burns GP; Liakakos P; Williams TJ; Snell GI
J Heart Lung Transplant; 2005 Apr; 24(4):489-92. PubMed ID: 15797754
[TBL] [Abstract][Full Text] [Related]
46. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.
Verleden GM; Verleden SE; Vos R; De Vleeschauwer SI; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM
Transpl Int; 2011 Jul; 24(7):651-6. PubMed ID: 21401732
[TBL] [Abstract][Full Text] [Related]
47. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.
Meyer KC; Raghu G; Verleden GM; Corris PA; Aurora P; Wilson KC; Brozek J; Glanville AR; ;
Eur Respir J; 2014 Dec; 44(6):1479-503. PubMed ID: 25359357
[TBL] [Abstract][Full Text] [Related]
48. Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation.
Brownback KR; Simpson SQ; Pitts LR; Polineni D; McGuirk JP; Ganguly S; Aljitawi OS; Lin TL; Singh A; Abhyankar S
J Clin Apher; 2016 Aug; 31(4):347-52. PubMed ID: 26031713
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.
Lama VN; Murray S; Mumford JA; Flaherty KR; Chang A; Toews GB; Peters-Golden M; Martinez FJ
Am J Respir Crit Care Med; 2005 Aug; 172(3):379-83. PubMed ID: 15894603
[TBL] [Abstract][Full Text] [Related]
50. Long-term clarithromycin therapy in the management of lung transplant recipients.
Benden C; Boehler A
Transplantation; 2009 May; 87(10):1538-40. PubMed ID: 19461491
[TBL] [Abstract][Full Text] [Related]
51. Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.
Brownback KR; Thomas LA; McGuirk JP; Ganguly S; Streiler C; Abhyankar S
Lung; 2017 Dec; 195(6):781-788. PubMed ID: 28894914
[TBL] [Abstract][Full Text] [Related]
52. Bronchodilator response at low lung volumes predicts bronchiolitis obliterans in lung transplant recipients.
Rajagopalan N; Maurer J; Kesten S
Chest; 1996 Feb; 109(2):405-7. PubMed ID: 8620713
[TBL] [Abstract][Full Text] [Related]
53. Relationship between FEV
Kemp R; Pustulka I; Boerner G; Smela B; Hofstetter E; Sabeva Y; François C
Respir Med; 2021 Nov; 188():106608. PubMed ID: 34517199
[TBL] [Abstract][Full Text] [Related]
54. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
Benden C; Haughton M; Leonard S; Huber LC
J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
[TBL] [Abstract][Full Text] [Related]
55. Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation.
Hachem R; Corris P
Transplantation; 2018 Jul; 102(7):1059-1065. PubMed ID: 29557913
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome.
Nathan SD; Shlobin OA; Reese E; Ahmad S; Fregoso M; Athale C; Barnett SD
Respir Med; 2009 Dec; 103(12):1816-21. PubMed ID: 19682883
[TBL] [Abstract][Full Text] [Related]
57. Bronchiolitis obliterans syndrome leads to a functional deterioration of the acinus post lung transplant.
Thompson BR; Hodgson YM; Kotsimbos T; Liakakos P; Ellis MJ; Snell GI; Verbanck S
Thorax; 2014 May; 69(5):487-8. PubMed ID: 24212890
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Kim SW; Rhee CK; Kim YJ; Lee S; Kim HJ; Lee JW
Respir Res; 2016 May; 17(1):63. PubMed ID: 27229850
[TBL] [Abstract][Full Text] [Related]
59. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation.
Hübner RH; Meffert S; Mundt U; Böttcher H; Freitag S; El Mokhtari NE; Pufe T; Hirt S; Fölsch UR; Bewig B
Eur Respir J; 2005 Mar; 25(3):494-501. PubMed ID: 15738294
[TBL] [Abstract][Full Text] [Related]
60. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome.
Fietta AM; Meloni F
Curr Med Chem; 2008; 15(7):716-23. PubMed ID: 18336286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
